Valuation: AstraZeneca Pharma India Limited

Market Cap 188B 1.96B 1.69B 1.59B 1.45B 2.72B 2.76B 18.67B 7.32B 93.88B 7.36B 7.2B 313B P/E 2025
186x
P/E 2026 103x
Enterprise Value 184B 1.92B 1.66B 1.56B 1.42B 2.67B 2.71B 18.34B 7.19B 92.19B 7.22B 7.07B 307B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
18.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-1.85%
1 week-5.51%
Current month-7.35%
1 month-6.45%
3 months-11.69%
6 months-15.53%
Current year-16.67%
1 week 7,490
Extreme 7490
7,912.3
1 month 7,490
Extreme 7490
8,497.7
Current year 7,490
Extreme 7490
9,219.25
1 year 7,490
Extreme 7490
9,850
3 years 4,014.65
Extreme 4014.65
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Director of Finance/CFO - 01/10/2023
Compliance Officer - 23/02/2026
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 52 30/09/2024
Director/Board Member - 08/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%-5.51%-10.76%+83.23% 2B
+3.63%+3.66%+79.88%+129.97% 1,093B
+0.55%+4.58%+53.44%+63.02% 653B
+1.74%+5.62%+27.42%+74.97% 458B
+1.80%+0.52%+41.20%+44.48% 355B
+1.24%+2.35%+25.99%+41.24% 294B
+2.07%+2.97%+2.27%+12.89% 248B
+2.54%+4.88%+47.68%+67.42% 230B
+1.05%-0.02%-13.96%-52.51% 203B
+2.36%+8.08%+24.47%+93.38% 178B
Average +1.46%+0.71%+27.76%+55.81% 371.25B
Weighted average by Cap. +2.04%+1.45%+45.79%+72.77%

Financials

2025 2026
Net sales 17.16B 179M 155M 146M 132M 249M 252M 1.71B 669M 8.58B 673M 658M 28.59B 22.76B 238M 205M 193M 175M 330M 335M 2.26B 887M 11.38B 892M 872M 37.91B
Net income 1.16B 12.08M 10.43M 9.82M 8.92M 16.78M 17.03M 115M 45.13M 579M 45.35M 44.37M 1.93B 1.88B 19.57M 16.9M 15.9M 14.45M 27.19M 27.59M 187M 73.11M 938M 73.48M 71.89M 3.12B
Net Debt -5B -52.23M -45.11M -42.44M -38.57M -72.55M -73.61M -498M -195M -2.5B -196M -192M -8.34B -3.37B -35.18M -30.38M -28.59M -25.98M -48.87M -49.58M -335M -131M -1.69B -132M -129M -5.62B
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
19/08/26 7,508.20 -1.85% 533
18/08/26 ₹7,649.85 +0.28% 144
17/08/26 ₹7,628.85 -1.61% 873
14/08/26 ₹7,753.70 -0.49% 158
13/08/26 ₹7,791.60 -1.44% 2,216
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock